Sab biotherapeutics provides company update and reports full year 2021 financial results

Sab executing on its strategy to build a proprietary immune and autoimmune disorders pipeline, including respiratory diseases that affect immunocompromised patients
SABS Ratings Summary
SABS Quant Ranking